Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm
Sipuleucel-T is an autologous cellular immunotherapy approved in the US for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). This significant advance for mCRPC treatment provides healthcare professionals with another effective therapy to ex...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Taylor & Francis
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839373/ |